ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,225Medicare Part D Prescriptions Filled, Including Refills

Rank: 117 out of 1269

$329K Total Retail Price of All Prescriptions

Rank: 331 out of 1269

223 Patients Receiving at Least One Drug in Part D
99%Patients 65 Years and Older
19% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Maryland
Lower avg

Schedule Two
Controlled Substances

11% of this provider’s 223 patients filled at least one prescription for a schedule two drug, compared to an average of 7%.

Schedule Three
Controlled Substances

6% of this provider’s 223 patients filled at least one prescription for a schedule three drug, compared to an average of 5%.

Risky Drugs to Seniors

0% of this provider’s 8,200 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

20% of this provider’s prescriptions were for brand-name drugs, compared to an average of 26%.

Prescription Price

$40 was the average price of a prescription from this provider, compared to $69 among peers.

Prescriptions per Patient

37 is the average number of prescriptions (including refills) per patient, compared to an average of 18.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Maryland
FUROSEMIDE 377 377 1 5
JANTOVEN 284 284 2 52
LEVOTHYROXINE SODIUM 261 261 3 4
LISINOPRIL 247 247 4 1
METOPROLOL TARTRATE 231 231 5 6
OMEPRAZOLE 215 215 6 8
PRAVASTATIN SODIUM 193 193 7 11
AMLODIPINE BESYLATE 183 183 8 2
CITALOPRAM HBR 157 157 9 21
ESCITALOPRAM OXALATE 141 141 10 58
SERTRALINE HCL 136 136 11 23
HYDROCHLOROTHIAZIDE 136 136 11 10
TRAMADOL HCL 131 131 13 16
TRAZODONE HCL 127 127 14 36
PANTOPRAZOLE SODIUM 123 123 15 18
MIRTAZAPINE 119 108 16 24
DONEPEZIL HCL 119 119 16 22
PREDNISONE 117 117 18 45
TAMSULOSIN HCL 96 96 19 31
ATENOLOL 92 92 20 14
SIMVASTATIN 89 89 21 3
LIDODERM 86 86 22 56
CLOPIDOGREL 80 80 23 32
ALENDRONATE SODIUM 78 78 24 28
KLOR-CON M20 77 77 25 60
LOSARTAN POTASSIUM 75 75 26 15
DIGOXIN 73 73 27 62
ATORVASTATIN CALCIUM 73 73 27 7
WARFARIN SODIUM 70 70 29 12
CIPROFLOXACIN HCL 69 69 30 66
QUETIAPINE FUMARATE 68 68 31 53
CELEBREX 66 66 32 95
METOPROLOL SUCCINATE 66 66 32 13
KLOR-CON M10 62 62 34 139
POLYETHYLENE GLYCOL 3350 60 60 35 50
CARVEDILOL 59 59 36 29
ISOSORBIDE MONONITRATE ER 57 57 37 63
LATANOPROST 56 56 38 143
CARBIDOPA-LEVODOPA 56 56 38 78
CYMBALTA 55 55 40 70
METFORMIN HCL 55 55 40 9
PAROXETINE HCL 54 43 42 71
SPIRIVA 53 53 43 64
DILTIAZEM 24HR ER 52 52 44 204
PLAVIX 51 51 45 47
DIOVAN 51 51 45 35
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Dec. 1, 2011.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.